Compare Quest Diagnostics Inc (DGX) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Kyndryl Holdings Inc — how do they compare? Quest Diagnostics Inc trades at $205.71 (market cap $22.80B), while Kyndryl Holdings Inc trades at $11.79 (market cap $2.56B). The key difference: Quest Diagnostics Inc is far larger — about 8.9× Kyndryl Holdings Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals.
| DGX | KD | |
|---|---|---|
Market Cap | $22.80B | $2.56B |
Sector | Health | Technology |
52-Week High | $216.02 | $39.47 |
52-Week Low | $166.42 | $10.59 |
Enterprise Value | $28.82B | $4.89B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Kyndryl Holdings (KD) trades at $12.32, up 2.92% with a bullish technical signal. The company shows improving fundamentals with 2025 net income turning positive at $252M after years of losses, though recent quarterly earnings missed expectations. Valuation remains attractive with P/E of 14.49 and EV/EBITDA of 3.19. Recent partnerships with Microsoft and AWS for AI solutions highlight strategic positioning.
Outlook remains cautiously optimistic with analyst consensus target of $14.33 offering 16% upside. Key risks include ongoing earnings volatility, internal control investigations, and high debt levels. The transformation toward higher-margin services provides growth potential, but execution risks and competitive pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
